BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, November 25, 2024
See today's BioWorld Asia
Home
» Covig-19 therapy fails to meet endpoints, but quest to find cure continues
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Covig-19 therapy fails to meet endpoints, but quest to find cure continues
April 13, 2021
By
Gina Lee
No Comments
HONG KONG – Covig-19, an anti-SARS-CoV-2 hyperimmune immunoglobulin therapy that Takeda Pharmaceutical Co. Ltd. developed alongside the Covig-19 Plasma Alliance, has failed to meet its endpoints in a global phase III trial.
BioWorld Asia
Clinical
